Current Approaches to the Management of Brain Metastases

Overview

Journal Nat Rev Clin Oncol

Specialty Oncology

Date 2020 Feb 22

PMID 32080373

Citations 225

Authors

John H Suh

Rupesh Kotecha

Samuel T Chao

Manmeet S Ahluwalia

Arjun Sahgal

Eric L Chang

Affiliations

Soon will be listed here.

Abstract

Brain metastases are a very common manifestation of cancer that have historically been approached as a single disease entity given the uniform association with poor clinical outcomes. Fortunately, our understanding of the biology and molecular underpinnings of brain metastases has greatly improved, resulting in more sophisticated prognostic models and multiple patient-related and disease-specific treatment paradigms. In addition, the therapeutic armamentarium has expanded from whole-brain radiotherapy and surgery to include stereotactic radiosurgery, targeted therapies and immunotherapies, which are often used sequentially or in combination. Advances in neuroimaging have provided additional opportunities to accurately screen for intracranial disease at initial cancer diagnosis, target intracranial lesions with precision during treatment and help differentiate the effects of treatment from disease progression by incorporating functional imaging. Given the numerous available treatment options for patients with brain metastases, a multidisciplinary approach is strongly recommended to personalize the treatment of each patient in an effort to improve the therapeutic ratio. Given the ongoing controversies regarding the optimal sequencing of the available and expanding treatment options for patients with brain metastases, enrolment in clinical trials is essential to advance our understanding of this complex and common disease. In this Review, we describe the key features of diagnosis, risk stratification and modern paradigms in the treatment and management of patients with brain metastases and provide speculation on future research directions.

Citing Articles

Deep learning radiomics for the prediction of epidermal growth factor receptor mutation status based on MRI in brain metastasis from lung adenocarcinoma patients.

Cao P, Jia X, Wang X, Fan L, Chen Z, Zhao Y BMC Cancer. 2025; 25(1):443.

PMID: 40075375 PMC: 11899356. DOI: 10.1186/s12885-025-13823-8.

Spatial-demographic analysis model for brain metastases distribution.

Zhang L, Che T, Xin B, Li S, Gong G, Wang X Radiol Med. 2025; 130(3):397-411.

PMID: 40019681 PMC: 11903647. DOI: 10.1007/s11547-025-01965-5.

Streamlit Application and Deep Learning Model for Brain Metastasis Monitoring After Gamma Knife Treatment.

Buga R, Buzea C, Agop M, Ochiuz L, Vasincu D, Popa O Biomedicines. 2025; 13(2).

PMID: 40002836 PMC: 11852629. DOI: 10.3390/biomedicines13020423.

Cancer brain metastasis: molecular mechanisms and therapeutic strategies.

Lu Y, Huang Y, Zhu C, Li Z, Zhang B, Sheng H Mol Biomed. 2025; 6(1):12.

PMID: 39998776 PMC: 11861501. DOI: 10.1186/s43556-025-00251-0.

Whole-Brain Radiotherapy Simultaneous Integrated Boost Intensity-Modulated Radiotherapy Combined With Anlotinib in the Treatment of Brain Metastases.

Tao W, Jiang C, Xie J, Liu W, Wang S, Zhang J Cancer Control. 2025; 32:10732748251319489.

PMID: 39951682 PMC: 11829290. DOI: 10.1177/10732748251319489.

References

Suh J . Stereotactic radiosurgery for the management of brain metastases. N Engl J Med. 2010; 362(12):1119-27. DOI: 10.1056/NEJMct0806951. View

Singh Achrol A, Rennert R, Anders C, Soffietti R, Ahluwalia M, Nayak L . Brain metastases. Nat Rev Dis Primers. 2019; 5(1):5. DOI: 10.1038/s41572-018-0055-y. View

Postmus P, Smit E . Prophylactic cranial irradiation for stage IV small cell lung cancer, live longer or reduce morbidity of brain metastases?. J Thorac Dis. 2017; 9(10):3572-3575. PMC: 5723843. DOI: 10.21037/jtd.2017.09.50. View

Scoccianti S, Ricardi U . Treatment of brain metastases: review of phase III randomized controlled trials. Radiother Oncol. 2011; 102(2):168-79. DOI: 10.1016/j.radonc.2011.08.041. View

Tsukada Y, Fouad A, PICKREN J, Lane W . Central nervous system metastasis from breast carcinoma. Autopsy study. Cancer. 1983; 52(12):2349-54. DOI: 10.1002/1097-0142(19831215)52:12<2349::aid-cncr2820521231>3.0.co;2-b. View

Sampson J, Carter Jr J, Friedman A, Seigler H . Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma. J Neurosurg. 1998; 88(1):11-20. DOI: 10.3171/jns.1998.88.1.0011. View

Nayak L, Quant Lee E, Wen P . Epidemiology of brain metastases. Curr Oncol Rep. 2011; 14(1):48-54. DOI: 10.1007/s11912-011-0203-y. View

Cagney D, Martin A, Catalano P, Redig A, Lin N, Lee E . Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study. Neuro Oncol. 2017; 19(11):1511-1521. PMC: 5737512. DOI: 10.1093/neuonc/nox077. View

Suki D, Khoury Abdulla R, Ding M, Khatua S, Sawaya R . Brain metastases in patients diagnosed with a solid primary cancer during childhood: experience from a single referral cancer center. J Neurosurg Pediatr. 2014; 14(4):372-85. DOI: 10.3171/2014.7.PEDS13318. View

10.

Goldman S, Echevarria M, Fangusaro J . Pediatric brain metastasis from extraneural malignancies: a review. Cancer Treat Res. 2007; 136:143-68. DOI: 10.1007/978-0-387-69222-7_8. View

11.

Mehta M, Rodrigus P, Terhaard C, Rao A, Suh J, Roa W . Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases. J Clin Oncol. 2003; 21(13):2529-36. DOI: 10.1200/JCO.2003.12.122. View

12.

Meyers C, Smith J, Bezjak A, Mehta M, Liebmann J, Illidge T . Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial. J Clin Oncol. 2004; 22(1):157-65. DOI: 10.1200/JCO.2004.05.128. View

13.

Schellinger P, Meinck H, Thron A . Diagnostic accuracy of MRI compared to CCT in patients with brain metastases. J Neurooncol. 2000; 44(3):275-81. DOI: 10.1023/a:1006308808769. View

14.

Sze G, Shin J, Krol G, JOHNSON C, Liu D, Deck M . Intraparenchymal brain metastases: MR imaging versus contrast-enhanced CT. Radiology. 1988; 168(1):187-94. DOI: 10.1148/radiology.168.1.3380956. View

15.

McGann G, Platts A . Computed tomography of cranial metastatic malignant melanoma: features, early detection and unusual cases. Br J Radiol. 1991; 64(760):310-3. DOI: 10.1259/0007-1285-64-760-310. View

16.

Albert F, Forsting M, Sartor K, Adams H, Kunze S . Early postoperative magnetic resonance imaging after resection of malignant glioma: objective evaluation of residual tumor and its influence on regrowth and prognosis. Neurosurgery. 1994; 34(1):45-60; discussion 60-1. DOI: 10.1097/00006123-199401000-00008. View

17.

Forsyth P, Petrov E, Mahallati H, Cairncross J, Brasher P, MacRae M . Prospective study of postoperative magnetic resonance imaging in patients with malignant gliomas. J Clin Oncol. 1997; 15(5):2076-81. DOI: 10.1200/JCO.1997.15.5.2076. View

18.

Patel T, McHugh B, Bi W, Minja F, Knisely J, Chiang V . A comprehensive review of MR imaging changes following radiosurgery to 500 brain metastases. AJNR Am J Neuroradiol. 2011; 32(10):1885-92. PMC: 7966021. DOI: 10.3174/ajnr.A2668. View

19.

Lin N, Lee E, Aoyama H, Barani I, Baumert B, Brown P . Challenges relating to solid tumour brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO group. Lancet Oncol. 2013; 14(10):e396-406. DOI: 10.1016/S1470-2045(13)70311-5. View

20.

Lin N, Wefel J, Lee E, Schiff D, van den Bent M, Soffietti R . Challenges relating to solid tumour brain metastases in clinical trials, part 2: neurocognitive, neurological, and quality-of-life outcomes. A report from the RANO group. Lancet Oncol. 2013; 14(10):e407-16. DOI: 10.1016/S1470-2045(13)70308-5. View